Astellas Pharma US, Inc.
3-11 Nihonbashi-Honcho 2-chome
About Astellas Pharma US, Inc.
516 articles with Astellas Pharma US, Inc.
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
Astellas is pleased to announce three recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. E
Astellas today announced that Lei Ding has been promoted to vice president, Payer Strategy, Contracts and Pricing.
The FDA approved Xospata for adult AML patients who have a FLT3 mutation as detected by an FDA-approved test. Of the 19,000 people in the United States who are estimated to be diagnosed with AML this year, nearly 40 percent will have a FLT3 mutation.
Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration
Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) announced today a new collaboration to develop, standardize and validate an evidence-based, oncology navigation-specific Acuity Tool.
Astellas today announced that Eloiza Domingo-Snyder has been appointed to executive director of Diversity and Inclusion, Astellas US.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
Astellas Details Progress and Commitment to Patients and the Community in the Company's Americas 2017 Corporate Social Responsibility Report Card
Astellas today issued its third-annual Americas Corporate Social Responsibility (CSR) Report Card.
Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer Congress
Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
Additional marketing award received for Best Video/TV Campaign
More than 800 Astellas Employees Volunteer for 16 Community Organizations as Part of Ninth Annual Changing Tomorrow Day
More than 800 Astellas employees joined together across four countries to help their communities and volunteer at 16 local nonprofit organizations.
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System.
Astellas today announced that Rodrigo Fernandez has been promoted to vice president, Latin America, based in Northbrook and reporting to Percival Barretto-Ko, president, Astellas Americas.
Shontelle was formerly the senior vice president, Medical Affairs for the Americas.
Pfizer and Astellas Pharma announced they have amended the protocols for two Phase III clinical trials, ARCHES and EMBARK, to evaluate Xtandi (enzalutamide) in hormone-sensitive prostate cancer (HSPC). Both trials will wrap sooner than planned as a result.
Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.